Intravenous Methadone Versus Intrathecal Morphine for Analgesia Following Cesarean Delivery
NCT06826742 is a phase 4 interventional trial sponsored by Mayo Clinic. As of 18 Nov 2026, it is completed. It studies Intrathecal Morphine and Intravenous line Methadone in Cesarean Delivery. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 12 Feb 2025 and a primary completion date of 14 Sept 2025.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06826742 |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Mayo Clinic |
| Enrollment | 30 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Cesarean Delivery |
| Drugs | Intrathecal Morphine and Intravenous line Methadone |
| Start | 12 Feb 2025 |
| Primary completion | 14 Sept 2025 |
| Study completion | 23 Sept 2025 |
| Last update posted | 21 Oct 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Emily E Sharpe, M.D.
Mayo Clinic
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic in Rochester
Rochester
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06826742
Each answer restates registry values shown on this page.
What is NCT06826742?
NCT06826742 is a phase 4 interventional trial sponsored by Mayo Clinic. It studies Intrathecal Morphine and Intravenous line Methadone in Cesarean Delivery.
Who leads NCT06826742?
The registry names Emily E Sharpe, M.D. (principal investigator, Mayo Clinic) as the overall official.
Where does NCT06826742 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06826742 study?
The registered drug and biological interventions are Intrathecal Morphine and Intravenous line Methadone.
When did NCT06826742 end?
The registry lists a primary completion date of 14 Sept 2025 and a study completion date of 23 Sept 2025. The sponsor last updated the record on 21 Oct 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.